Yes, it seems an awful lot for the current program given that total research and development costs last year were under $5m, they are half way through the trial, and they have @ $25m in cash left. Either there has been a complete blow-out of costs due to having to manufacture additional compound, or they are planning more than one trial. They have mentioned an additional $3m towards scale up of manufacturing though and I would assume that includes compound for the current trial.
There are only another 8 patients left to dose, so an explanation of why this is costing so much would be appreciated.
- Forums
- ASX - By Stock
- renaissance capital
Yes, it seems an awful lot for the current program given that...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)